Last close As at 05/08/2026
—
— 0.00 (0.00%)
Market capitalisation
—
Research: Consumer
PPHE continues to please, with resilient H1 operating results complemented by first-time disclosure of EPRA reporting, which highlights its real estate business with EPRA NAV of £24.21 at June 2018, significantly ahead of the current share price. A fine record of value creation (21% CAGR in NAV over the seven years to end-2017, as newly presented) should underpin the company’s ability to leverage on its assets, in addition to reinvestment potential from £152m excess cash. H1 saw maintained like-for-like EBITDA against a “very strong” comparative in London, PPHE’s major market, and renovations in the Netherlands. Encouraging trading in its seasonally stronger H2 supports guidance that 2018 expectations are unchanged. The interim dividend is raised by 45%.
PPHE Hotel Group |
Asset value growth to the fore |
Half-year results |
Travel & leisure |
4 October 2018 |
Share price performance
Business description
Next events
Analysts
PPHE Hotel Group is a research client of Edison Investment Research Limited |
|||||||||||||||||||||||||||||||||||||||||||||||||
PPHE continues to please, with resilient H1 operating results complemented by first-time disclosure of EPRA reporting, which highlights its real estate business with EPRA NAV of £24.21 at June 2018, significantly ahead of the current share price. A fine record of value creation (21% CAGR in NAV over the seven years to end-2017, as newly presented) should underpin the company’s ability to leverage on its assets, in addition to reinvestment potential from £152m excess cash. H1 saw maintained like-for-like EBITDA against a “very strong” comparative in London, PPHE's major market, and renovations in the Netherlands. Encouraging trading in its seasonally stronger H2 supports guidance that 2018 expectations are unchanged. The interim dividend is raised by 45%.
Year end |
Revenue (£m) |
EBITDA |
PBT* |
EPS* |
DPS |
EV/EBITDA |
12/16 |
272.5 |
94.1 |
34.2 |
69.9 |
21.0** |
13.4 |
12/17 |
325.1 |
107.3 |
34.5 |
64.2 |
24.0 |
10.1 |
12/18e |
340.0 |
112.0 |
38.0 |
68.8 |
34.0 |
10.0 |
12/19e |
350.0 |
118.0 |
44.0 |
81.6 |
36.0 |
9.3 |
Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments. **Plus 100p special dividend.
H1 defiance
Despite headwinds in PPHE’s two main first-half markets (London and Amsterdam), like-for-like EBITDA held steady on 4% higher revenue. While regional performance is not disclosed, we assume core London RevPAR to have matched the market, which was down 1% against recovery-led +10% buoyancy in H117. The 7% rise in UK EBITDA was driven by key 2017 openings, Waterloo and Park Royal, which are maturing well. Also as expected, the Netherlands shortfall (EBITDA down 5%) was due to renovations (estimated 7% rooms off with associated disruption), notably at flagship Victoria Amsterdam. By contrast, Croatia, usually lossmaking in H1, moved into profit, thanks to 10% higher revenue, boosted by a favourable calendar and investment. Germany and Hungary gained across the board (EBITDA up by 26%).
More of the same
On stated investment plans, we remain comfortable with our H218 forecasts, bar slight adjustment to mix and net debt (raised 4%). EBITDA growth will be driven by investment in London, Croatia and Amsterdam, while H1 shows costs in core London can be contained (we still expect lower y-o-y margin). 2019 is less clear, as management focuses on exploiting flexibility post-Waterloo and Arena fund-raising.
Valuation: Way to go
While refinancing valuations had drawn attention to substantial hidden reserves, EPRA reporting should enhance recognition of PPHE’s investment case. EPRA NAV of £24.21 at June 2018 means an excess of c £680m over book value. Likely investment activity should accentuate this, given the strong development record. In operational terms, at 10x 2018e EV/EBITDA excluding the Waterloo finance lease, the rating compares well with an average of c 11x 2018e for branded European peers.
Financials
Exhibit 1: Analysis of revenue and profit
Year-end December (£m) |
H117 |
H217 |
FY17 |
H118 |
H218e |
FY18e |
2019e |
|
Revenue |
||||||||
UK |
||||||||
London |
||||||||
RevPAR |
£130 |
£150 |
£140 |
£128 |
£152 |
£140 |
£140 |
|
Change |
+10% |
Flat |
+4% |
-1% |
+1% |
Flat |
Flat |
|
Available rooms |
2052* |
2052* |
2052* |
2052* |
2052* |
2052* |
2072* |
|
Room revenue |
48.2 |
56.3 |
104.5 |
47.5 |
57.5 |
105.0 |
106.0 |
|
Non-room revenue |
22.5 |
23.0 |
45.5 |
22.2 |
23.3 |
45.5 |
46.0 |
|
Existing revenue |
70.7 |
79.3 |
150.0 |
69.7 |
80.8 |
150.5 |
152.0 |
|
Waterloo + Park Royal** |
9.8 |
14.2 |
24.0 |
14.5 |
18.5 |
33.0 |
38.5 |
|
Total London revenue |
80.5 |
93.5 |
174.0 |
84.2 |
99.3 |
183.5 |
190.5 |
|
Leeds and Nottingham |
5.1 |
6.7 |
11.8 |
5.4 |
7.1 |
12.5 |
12.5 |
|
UK |
85.6 |
100.2 |
185.8 |
89.6 |
106.4 |
196.0 |
203.0 |
|
Netherlands (€m)*** |
28.9 |
25.2 |
54.1 |
28.2 |
27.8 |
56.0 |
58.0 |
|
Exchange rate |
1.16 |
1.12 |
1.14 |
1.14 |
1.14 |
1.14 |
1.14 |
|
Netherlands |
24.9 |
22.4 |
47.3 |
24.8 |
24.2 |
49.0 |
51.0 |
|
Croatia (HRKm) |
125.2 |
354.6 |
479.8 |
137.3 |
363.7 |
501.0 |
513.0 |
|
Exchange rate |
8.64 |
8.40 |
8.52 |
8.42 |
8.28 |
835 |
8.28 |
|
Croatia |
14.5 |
41.8 |
56.3 |
16.3 |
43.7 |
60.0 |
62.0 |
|
Germany and Hungary**** |
14.4 |
16.3 |
30.7 |
15.9 |
14.1 |
30.0 |
29.0 |
|
Owned & leased hotels |
139.4 |
180.7 |
320.1 |
146.6 |
188.4 |
335.0 |
345.0 |
|
Management and holdings |
2.4 |
2.6 |
5.0 |
2.2 |
2.8 |
5.0 |
5.0 |
|
TOTAL |
141.8 |
183.3 |
325.1 |
148.8 |
191.2 |
340.0 |
350.0 |
|
EBITDA |
||||||||
UK |
||||||||
London |
||||||||
Existing |
23.4 |
29.1 |
52.5 |
22.5 |
29.0 |
51.5 |
50.5 |
|
Margin |
33% |
37% |
35% |
32% |
36% |
34% |
33% |
|
Waterloo + Park Royal** |
1.8 |
4.2 |
6.0 |
4.5 |
5.9 |
10.4 |
12.3 |
|
Total London EBITDA |
25.2 |
33.3 |
58.5 |
27.0 |
34.9 |
61.9 |
62.8 |
|
Leeds and Nottingham |
0.8 |
1.2 |
2.0 |
0.9 |
1.2 |
2.1 |
2.2 |
|
UK |
26.0 |
34.5 |
60.5 |
27.9 |
36.1 |
64.0 |
65.0 |
|
Netherlands (€m)*** |
8.8 |
6.4 |
15.2 |
8.1 |
7.4 |
15.5 |
17.3 |
|
Exchange rate |
1.16 |
1.12 |
1.14 |
1.14 |
1.14 |
1.14 |
1.14 |
|
Netherlands |
7.5 |
5.8 |
13.3 |
7.1 |
6.4 |
13.5 |
15.2 |
|
Croatia (HRKm) |
Neg. |
159.1 |
159.1 |
0.8 |
167.7 |
167.5 |
182.0 |
|
Exchange rate |
8.64 |
8.40 |
8.51 |
8.42 |
8.28 |
8.35 |
8.28 |
|
Croatia** |
Neg. |
18.7 |
18.7 |
0.1 |
19.9 |
20.0 |
22.0 |
|
Germany and Hungary**** |
1.7 |
2.6 |
4.3 |
2.1 |
2.9 |
5.0 |
5.3 |
|
Owned & leased hotels |
35.2 |
61.6 |
96.8 |
37.2 |
65.3 |
102.5 |
107.5 |
|
Management and holdings |
4.7 |
5.8 |
10.5 |
3.4 |
6.1 |
9.5 |
10.5 |
|
TOTAL |
39.9 |
67.4 |
107.3 |
40.6 |
71.4 |
112.0 |
118.0 |
Source: Edison Investment Research. Note: *Rooms off at Sherlock Holmes (estimated 30 in 2017 and 2018 and 10 in 2019). **December 2016 Waterloo (494 rooms) and April 2017 Park Royal (212 rooms). ***Rooms off notably in Amsterdam (Victoria H217 and H118 and Vondelpark H218 and H119). ****Termination of Dresden lease (174 rooms) and rooms off at art’otel berlin kudamm (estimated 50 in H218 and 2019).
Exhibit 2: Financial summary
£000s |
2015 |
2016 |
2017 |
2018e |
2019e |
||
Year-end 31 December |
IFRS |
IFRS |
IFRS |
IFRS |
IFRS |
||
PROFIT & LOSS |
|||||||
Revenue |
|
|
218,700 |
272,500 |
325,100 |
340,000 |
350,000 |
EBITDA |
|
|
80,100 |
94,100 |
107,300 |
112,000 |
118,000 |
Operating Profit (before amort and except) |
|
63,100 |
70,900 |
75,400 |
80,000 |
86,000 |
|
Intangible Amortisation |
(2,000) |
(2,500) |
(2,400) |
(2,500) |
(2,500) |
||
Operating Profit |
61,100 |
68,400 |
73,000 |
77,500 |
83,500 |
||
Net Interest |
(29,300) |
(34,900) |
(40,600) |
(42,000) |
(42,000) |
||
Associates |
(2,000) |
(1,800) |
(300) |
0 |
0 |
||
Exceptionals |
(1,800) |
6,500 |
(400) |
11,300 |
0 |
||
Profit Before Tax (norm) |
|
|
31,800 |
34,200 |
34,500 |
38,000 |
44,000 |
Profit Before Tax (FRS 3) |
|
|
28,000 |
38,200 |
31,700 |
46,800 |
41,500 |
Tax |
1,200 |
(100) |
(1,700) |
(2,000) |
(2,500) |
||
Profit After Tax (norm) |
33,000 |
34,100 |
32,800 |
36,000 |
41,500 |
||
Profit After Tax (FRS 3) |
29,200 |
38,100 |
30,000 |
44,800 |
39,000 |
||
Average Number of Shares Outstanding (m) |
41.8 |
42.2 |
42.2 |
42.3 |
42.3 |
||
EPS - normalised (p) |
|
|
76.1 |
69.9 |
64.2 |
68.8 |
81.6 |
EPS - normalised fully diluted (p) |
|
|
76.1 |
69.9 |
64.2 |
68.8 |
81.6 |
EPS - (IFRS) (p) |
|
|
69.9 |
83.2 |
57.6 |
89.4 |
74.9 |
Dividend per share (p) |
20.0 |
21.0 |
24.0 |
34.0 |
36.0 |
||
EBITDA Margin (%) |
36.6 |
34.5 |
33.0 |
32.9 |
33.7 |
||
Operating Margin (before GW and except.) (%) |
28.9 |
26.0 |
23.2 |
23.5 |
24.6 |
||
BALANCE SHEET |
|||||||
Fixed Assets |
|
|
885,600 |
1,122,300 |
1,220,200 |
1,253,000 |
1,233,000 |
Intangible Assets |
21,900 |
25,200 |
23,600 |
23,000 |
23,000 |
||
Tangible Assets |
687,500 |
947,200 |
1,037,200 |
1,074,000 |
1,055,000 |
||
Income units sold to private investors |
125,500 |
122,500 |
121,200 |
118,000 |
115,000 |
||
Investments |
50,700 |
27,400 |
38,200 |
38,000 |
40,000 |
||
Current Assets |
|
|
71,700 |
195,600 |
319,800 |
261,000 |
276,000 |
Restricted deposits |
3,200 |
25,500 |
25,500 |
25,000 |
25,000 |
||
Stocks |
1,000 |
2,400 |
2,700 |
3,200 |
3,200 |
||
Debtors |
9,100 |
12,600 |
13,400 |
13,800 |
13,800 |
||
Cash |
50,600 |
144,700 |
265,700 |
205,000 |
220,000 |
||
Other |
7,800 |
10,400 |
12,500 |
14,000 |
14,000 |
||
Current Liabilities |
|
|
(59,900) |
(173,000) |
(93,100) |
(76,000) |
(80,000) |
Creditors |
(48,500) |
(54,700) |
(60,200) |
(61,000) |
(60,000) |
||
Deposits from unit holders |
0 |
0 |
0 |
0 |
0 |
||
Short term borrowings |
(11,400) |
(118,300) |
(32,900) |
(15,000) |
(20,000) |
||
Long Term Liabilities |
|
|
(629,500) |
(814,700) |
(1,006,000) |
(973,000) |
(948,000) |
Long term borrowings |
(440,100) |
(642,100) |
(666,900) |
(655,000) |
(640,000) |
||
Financial liability to unit holders |
(136,200) |
(134,000) |
(131,600) |
(128,000) |
(128,000) |
||
Other long term liabilities |
(53,200) |
(38,600) |
(207,500) |
(190,000) |
(180,000) |
||
Net Assets |
|
|
267,900 |
330,200 |
440,900 |
465,000 |
481,000 |
CASH FLOW |
|||||||
Operating Cash Flow |
|
|
83,200 |
79,500 |
114,000 |
112,000 |
118,000 |
Net Interest |
(32,500) |
(37,300) |
(43,100) |
(41,000) |
(41,000) |
||
Tax |
(100) |
0 |
(700) |
(1,400) |
(2,000) |
||
Capex |
(63,100) |
(87,300) |
(107,000) |
(55,000) |
(35,000) |
||
Acquisitions/disposals |
(3,600) |
(64,300) |
152,400 |
(35,000) |
0 |
||
Exchange rate |
6,000 |
(26,700) |
(9,000) |
1,000 |
0 |
||
Dividends |
(8,300) |
(50,600) |
(9,300) |
(12,500) |
(14,800) |
||
Other |
(5,800) |
(500) |
79,500 |
0 |
(200) |
||
Net Cash Flow |
(24,200) |
(187,200) |
176,800 |
(31,900) |
25,000 |
||
Opening net debt/(cash) |
|
|
373,500 |
397,700 |
584,900 |
408,100 |
440,000 |
HP finance leases initiated |
0 |
0 |
0 |
0 |
0 |
||
Other |
0 |
0 |
0 |
0 |
0 |
||
Closing net debt/(cash) |
|
|
397,700 |
584,900 |
408,100 |
440,000 |
415,000 |
Source: PPHE, Edison Investment Research
|
|
Healthperm’s H118 results showed strong revenue growth of 188% and a 281% rise in gross profit. Revenue was boosted by a 188% rise in the number of candidates deployed and gross profit has benefited from an improved mix. The company remains loss making as its ramp-up phase continues but the outlook is positive, supported by a good run of contract wins and entry into new markets. We have maintained our estimates and valuation.